- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Shoring Up the ACA; Alzheimer's Drugs; Hispanics in Clinical Trials
Schumer Offers ACA Fixes
With not enough Senate Republicans on board to pass legislation to repeal and replace, or even just repeal, the Affordable Care Act (ACA), Senate Minority Leader Charles Schumer (D-New York) is offering is own ideas on how to proceed. According to The Washington Post, Schumer has provided 3 ways Democrats and Republicans can work together to fix the ACA. However, he did tell his party members that no deals can include tax cuts for wealthy Americans or cuts to Medicaid.
Alzheimer’s Drug Pipeline Booming
The last Alzheimer’s drug to be approved in the United States was in 2003, but that may change soon. There are 27 drugs to treat Alzheimer’s disease in phase 3 clinical trials. Overall, researchers expect nearly 3 dozen new drugs could reach the market in the next 5 years, despite decades of failed drugs in the space and underinvestment. By 2050, there could be as many as 16 million Americans with Alzheimer’s disease.
Few Hispanics Participate in Clinical Trials
A report from Kaiser Health News highlighted how Hispanics are often left out of clinical trials, with detrimental effects. Enrollment in clinical trials provides access to experimental, cutting-edge treatments, which means they could be left out of getting access to potential cures. In addition, lack of representation in clinical trials means researchers have less data on how drugs work among Hispanics. A new campaign from the FDA is trying to fix the situation by educating Hispanics about medical studies.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
